Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Signs of myopathy detected before muscle formation


An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself
muscle fiber muscle fiber

Virginie Mournetas* and the Muscular Diseases team headed by Christian Pinset at I-Stem (Inserm UMR 861, AFM-Téléthon) have shown that molecular dysregulations associated with Duchenne muscular dystrophy appear during embryonic development before muscle tissues even start to develop. The combination of an in vitro cellular model of muscle formation created from pluripotent stem cells and a multiomic approach enabled this discovery.

Duchenne muscular dystrophy (DMD) is a rare genetic disease occurring in roughly 1 out of 5000 male births and causing progressive muscle degeneration. The disease is usually diagnosed around the age of four, when muscle damage has already become significant. The efficacy of certain treatments may be hampered by this belated diagnosis, which is particularly regrettable given that current findings, some born of research at I-Stem, suggest that the disease may appear before birth. Indeed, one of the laboratory’s objectives is to better identify the moment at which the disease begins to manifest.

 

The I-Stem Muscular Diseases team designed an original study on DMD onset involving a protocol to guide iPS cell differentiation toward the muscle cell phenotype. Their protocol faithfully reproduced the key steps in myogenesis, (i.e., the formation of skeletal muscle during embryonic development): first the formation of the mesoderm, then the somites (an intermediate structure) and through to the development of myotubes (see photo), a precursor to muscle fibers. They used the protocol on iPS cells derived from either healthy people or diseased patients. Multiomics analyses (transcriptomics, microRNA, proteomics) were done at five time intervals during the 25 days of myotube differentiation to determine molecular activity in the healthy or pathological cells.

 

As early as the somite stage, 10% of the pathological transcriptomes (indicating the genes expressed by the cells) showed dysregulations compared to the healthy transcriptomes. Notably, those dysregulations concerned mitochondrial genes, known for their role in DMD.

 

This unprecedented study demonstrating a very early manifestation of DMD during embryonic development and even upstream of muscle formation itself suggests a need for a reappraisal of the disease’s natural history. Particularly, the defective dystrophin protein, which is highly deleterious to muscle fibers and the cause of DMD, could also have other effects. This aspect merits exploration as it may explain some non-muscular DMD symptoms. Toward that goal, all of the study’s analyses have been grouped in a database available to the scientific community.

  • Virginie Mournetas

    Virginie Mournetas had benefitted from a Fondagen/Genopole research grant for an initial postdoctoral project at I-Stem. That project preceded several others, including the one described here.

  • Induced Pluripotent Stem (iPS)

    Induced Pluripotent Stem (iPS) cells are created by collecting differentiated cells, those of the skin for example, and genetically reprogramming them back to the pluripotent state.

References

Journal of Cachexia, Sarcopenia and Muscle (2021)

Myogenesis modelled by human pluripotent stem cells: a multi‐omic study of Duchenne myopathy early onset. .
doi : 10.1002/jcsm.12665

Database

Designed by the research team, to access this link: https://muscle-dmd.omics.ovh/

Article posted on 10 June 2021

Share
Highlights

Latest news


traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.

Discover
SYSFATE

Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

Discover
Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

Discover
LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

Discover
NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

Discover
Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

Seeing in high resolution at the Structural Biology Platform

With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.

Discover
MSCA COFUND 2020 - ApogeeBio Laureate

COFUND-MSCA2020 : ApogeeBio chosen by the EC

Submitted by Genopole and its on-site partners, the ApogeeBio project for research grants has been selected by the European Commission for Marie Skłodowska-Curie Actions co-funding (MSCA-Cofund-2020).

Discover
Genhotel -  fibroblastes, cancer & Polyarthrite

Metabolic reprogramming involved in rheumatoid arthritis and cancer

The researchers from GenHotel (University of Évry-Paris Saclay, Genopole) have shed light on certain aspects common to rheumatoid arthritis and cancer.

Discover
AB Science L. Gros

Multiple sclerosis and COVID-19: promising results from AB Science

AB Science has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis.

Discover
Placton - Tara Oceans

Bioinformatics and Tara Oceans

A team from the Genomics Metabolics Laboratory (Genoscope – CEA/CNRS/University of Évry) has developed a bioinformatics method for environmental genomics analyses able to identify species and associations of species.

Discover
Globules rouges - Avancées scientifiques

CRISPR-Cas9 for blood and metabolic diseases – Integrare

In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.

Discover
Généthon - Genopole's Laboratory

Treating more patients with gene therapies – Généthon

A Genethon team has successfully inhibited immune response to adeno-associated virus vectors, and in so doing, opened potential paths for treating more patients with gene therapies.

Discover
COVID-19 Disease Map

A single interactive map for all that is known on COVID-19

The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

Discover
cellular membrane

Mapping membrane nanotubes – Lambe

A team from the Genopole-accredited Laboratory for Analysis and Modeling in Biology and the Environment (Lambe) has developed an experimental technique to study cell membrane nanotubes. These largely unknown structures play an essential role in cellular biomolecule transport.

Discover
Laboratory

Toward the industrialization of gene therapies -Polytheragene

Polytheragene is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.

Discover
Jean Weissenbach

Jean Weissenbach: a portrait

Jean Weissenbach, a pioneer in France for the exploration of the human genome and a scientific icon at Genopole, talks about his career in an interview published 18 March 2020 in CNRS News.

Discover
cellular membrane

A nanopore to identify amino acids – Lambe

A team from the Laboratory for Analysis and Modeling in Biology and the Environment (Lambe – University of Évry/University of Cergy-Pontoise/CNRS) used a natural aerolysin nanopore to successfully identify 13 of the 20 amino acids that make up proteins.

Discover
Genopole - European projects

Green light from Europe for the Genopole-coordinated project GEN.ERA

Le projet européen GEN.ERA*, coordonné par Genopole, est sélectionné par la Commission européenne. Il vise à renforcer par une coopération entre clusters, l’internationalisation d’entreprises du secteur de la génomique au-delà du continent européen.

Discover
actus

New accomplishment in gene therapies

A clinical trial for a gene therapy to treat a severe immunodeficiency has provided highly promising initial results.

Discover
View all >
With support